Search

Your search keyword '"Carpenter, Shannon L."' showing total 230 results
Start Over Author "Carpenter, Shannon L."
230 results on '"Carpenter, Shannon L."'

1. Practical considerations and consensus opinion for children’s hospital–based inpatient hemostasis and thrombosis (HAT) consultative services: Communication from the ISTH SSC Subcommittee on Pediatric/Neonatal Thrombosis and Hemostasis

Author

Woods, Gary M., Raffini, Leslie, Brandão, Leonardo R., Jaffray, Julie, Branchford, Brian R., Ng, Christopher J., Sartain, Sarah E., Pak, Jennifer, Male, Christoph, Zia, Ayesha, Rizzi, Mattia, Sirachainan, Nongnuch, Faustino, Edward Vincent S., Carpenter, Shannon L., and Goldenberg, Neil A.

Published
2022
Full Text
View/download PDF

5. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome

Author

Carpenter, Shannon L., Goldman, Jennifer, Sherman, Ashley K., Selewski, David T., Kallash, Mahmoud, Tran, Cheryl L., and Seamon, Meredith

Subjects
Nephrotic syndrome -- Complications and side effects -- Care and treatment -- Research, Thromboembolism -- Risk factors -- Diagnosis -- Care and treatment -- Research, Health
Abstract

Background Nephrotic syndrome (NS) results in hypercoagulability and increased risk of infection. Furthermore, infection increases the risk of venous thromboembolism (VTE). Our objective was to determine the prevalence of infection, VTE, and the associated outcomes among a cohort of hospitalized children with NS. Methods All children with NS admitted to 17 pediatric hospitals across North America from 2010 to 2012 were included. Prevalence of infection and VTE was determined. Wilcoxon rank-sum and logistic regression were performed. Results Seven-hundred thirty hospitalizations occurred among 370 children with NS. One-hundred forty-eight children (40%) had [greater than or equal to] 1 infection (211 episodes) and 11 (3%) had VTE. Those with VTE had infection more frequently (p = 0.046) and were younger at NS diagnosis (3.0 vs. 4.0 years; p = 0.008). The most common infectious pathogen identified was Streptococcus pneumoniae. The median hospital length of stay for those with infection [10 vs 5 days (p < 0.0001)] or VTE [22 vs 6 days (p < 0.0001)] was longer than those without either complication. Of those with infection, 13% had an intensive care unit (ICU) stay compared with 3.3% of those without infection. Median ICU stay was 4 days in those with VTE compared to 0 days in those without (p < 0.001). By logistic regression, only the number of ICU days was associated with VTE (OR 1.074, 95% CI 1.013-1.138). Conclusions Hospitalized children with NS have high rates of infection. Presence of VTE was associated with infection. Both were associated with longer hospitalizations and ICU stays., Author(s): Shannon L. Carpenter [sup.1] , Jennifer Goldman [sup.1] , Ashley K. Sherman [sup.1] , David T. Selewski [sup.2] , Mahmoud Kallash [sup.3] , Cheryl L. Tran [sup.4] , Meredith [...]

Published
2019
Full Text
View/download PDF

7. Long‐term follow‐up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma‐derived factor VIII (Koate) that contains ADAMTS13.

Author

Chrisentery‐Singleton, Tammuella, Boggio, Lisa N., Carcao, Manuel D., Ibrahimi, Sami, Khan, Osman, Mahajerin, Arash, Rajasekhar, Anita, Sharma, Vivek, Steele, MacGregor, Torres, Marcela, Rodino, Frank J., and Carpenter, Shannon L.

Subjects
BLOOD coagulation factor VIII, THROMBOCYTOPENIA, VON Willebrand factor, PLASMA products, THROMBOTIC thrombocytopenic purpura
Abstract

Background: Hereditary thrombotic thrombocytopenia purpura (hTTP) is an ultra‐rare disorder resulting from an inherited deficiency of ADAMTS13, a von Willebrand factor (VWF)‐cleaving metalloprotease. The plasma‐derived factor VIII/VWF Koate (FVIII/VWFKoate) has been shown to contain ADAMTS13, allowing for its use to treat hTTP at home by the patient/caregiver. Aim: Based on prior demonstration of safe and effective use of FVIII/VWFKoate in eight patients with hTTP, we conducted a retrospective study to gather additional data regarding the use of FVIII/VWFKoate for hTTP. Methods: This was a multicentre, retrospective, noninterventional chart review of patients who had received FVIII/VWFKoate for the management of hTTP. Data collected included demographics, medical history, relevant family history, past use and tolerability of fresh frozen plasma, and details regarding FVIII/VWFKoate therapy. Results: The cohort included 11 patients (seven males, four females) with hTTP, ranging in age at study entry from 2 to 28 years. The average duration of FVIII/VWFKoate therapy was 4.8 years (range, 0.5–6.5 years). Among nine patients using FVIII/VWFKoate as prophylaxis, the normalized annual rate of breakthrough TTP episodes ranged from 0.2 to 1.1 episodes/year. All nine patients who received FVIII/VWFKoate prophylaxis had thrombocytopenia recorded at baseline, while eight (88.9%) did not have thrombocytopenia after using FVIII/VWFKoate. There was one AE (unspecified) attributed to FVIII/VWFKoate. Conclusion: These data suggest that FVIII/VWFKoate is a safe and well‐tolerated source of the missing ADAMTS13 enzyme in patients with hTTP, producing a marked reduction in thrombocytopenia prevalence, low frequency of TTP episodes, and with the added benefit of self‐ or caregiver‐administration. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding

Author

Ragni, Margaret V., primary, Young, Guy, additional, Batsuli, Glaivy, additional, Bisson, Emily, additional, Carpenter, Shannon L., additional, Croteau, Stacy E., additional, Cuker, Adam, additional, Curtis, Randall G., additional, Denne, Michael, additional, Ewenstein, Bruce, additional, Federizo, Amber, additional, Frick, Neil, additional, Funkhouser, Kerry, additional, George, Lindsey A., additional, Hoots, W. Keith, additional, Jobe, Shawn M., additional, Krava, Emily, additional, Langmead, Christopher James, additional, Lewis, Roger J., additional, López, José, additional, Malec, Lynn, additional, Mann, Ziva, additional, Miles, Moses E., additional, Neely, Emma, additional, Neufeld, Ellis J., additional, Pierce, Glenn F., additional, Pipe, Steven W., additional, Pitler, Lisa R., additional, Raffini, Leslie, additional, Schnur, Kathaleen M., additional, and Shavit, Jordan A., additional

Published
2023
Full Text
View/download PDF

10. Depression and anxiety in persons with Von Willebrand disease

Author

Roberts, Jonathan C., primary, Kulkarni, Roshni, additional, Kouides, Peter A., additional, Sidonio, Robert F., additional, Carpenter, Shannon L., additional, Konkle, Barbara A., additional, Wu, Joanne, additional, Ullman, Megan M., additional, Curtis, Randall, additional, Baker, Judith R., additional, Crook, Nicole, additional, and Nichol, Michael B., additional

Published
2022
Full Text
View/download PDF

11. Clinical Characteristics Impacting Health-Related Quality of Life in Persons with Von Willebrand Disease

Author

Carpenter, Shannon L, primary, Wu, Joanne, additional, Roberts, Jonathan C., additional, Kulkarni, Roshni, additional, Kouides, Peter A., additional, Sidonio, Jr., Robert F., additional, Konkle, Barbara, additional, Baker, Judith, additional, Ullman, Megan M., additional, Curtis, Randall, additional, Crook, Nicole, additional, and Nichol, Michael B., additional

Published
2022
Full Text
View/download PDF

12. Long-Term Follow-up of Patients with Congenital Thrombotic Thrombocytopenia Purpura Receiving Plasma-Derived Factor VIII Containing (Koate®)

Author

Chrisentery-Singleton, Tammuella, primary, Boggio, Lisa N, additional, Carcao, Manuel, additional, Ibrahimi, Sami, additional, Khan, Osman, additional, Mahajerin, Arash, additional, Rajasekhar, Anita, additional, Sharma, Vivek, additional, Steele, MacGregor, additional, Torres, Marcela, additional, and Carpenter, Shannon L, additional

Published
2022
Full Text
View/download PDF

13. U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics

Author

Carpenter, Shannon L, primary, Chandler, Martin, additional, Guerrera, Michael F, additional, Malec, Lynn, additional, Manuel, Matthew, additional, Recht, Michael, additional, Reiss, Ulrike, additional, Sidonio, Jr., Robert F., additional, Tarango, Cristina, additional, Van den Berg, Marijke, additional, Wang, Michael, additional, and Thornburg, Courtney D., additional

Published
2022
Full Text
View/download PDF

20. Depression and anxiety in persons with Von Willebrand disease.

Author

Roberts, Jonathan C., Kulkarni, Roshni, Kouides, Peter A., Sidonio, Robert F., Carpenter, Shannon L., Konkle, Barbara A., Wu, Joanne, Ullman, Megan M., Curtis, Randall, Baker, Judith R., Crook, Nicole, and Nichol, Michael B.

Subjects
VON Willebrand disease, GENERALIZED anxiety disorder, HEALTH facilities, ANXIETY, MENTAL health screening, MENTAL depression
Abstract

Objective: We assessed sociodemographic and clinical characteristics associated with depression and anxiety in individuals with Von Willebrand disease (VWD) aged ≥12 years. Methods: The study collected data on patients' sociodemographic, joint problems and health‐related quality of life (HRQoL) using EQ‐5D‐3L, 8‐item patient health questionnaire for depression and 7‐item Generalized Anxiety Disorder Questionnaire from participants in seven geographically diverse US haemophilia treatment centres. Results: Analyses included 77 participants. The rates of depression and anxiety were 63.6% and 58.3%, respectively. Persons with low VWF displayed higher rates of depression (86.7%) or anxiety (69.2%) compared to those with VWD (58.1%, p =.04 for depression, and 55.9%, p =.38 for anxiety). Logistic regression analyses demonstrated that having joint problems (odds ratio [OR] = 6.3, confidence interval [CI] = 2.0–20.1) was the most important variable associated with depression, followed by being single, divorced, widowed, or separated in adult participants or parents of participants age < 18 years (OR = 7.0, CI = 1.7–29.0. The most important variable associated with anxiety was being single or lacking a partner (OR = 10.8, CI = 2.5–47.5), followed by age 12–17 years old (OR = 6.7, CI = 1.6–26.9), or having worse health compared to 3‐months ago (OR = 12.3, CI = 1.3‐116.2). Mean covariates adjusted EQ visual analogue scale score was significantly lower among persons with depression (68.77 ± 3.15 vs. 77.58 ± 4.24, p =.03) than those without depression. Conclusions: Our study revealed concerning levels of depression and anxiety in this VWD sample. Lack of social support was determined an important factor associated with depression and anxiety in this sample. Mental health screening is critical in VWD clinical evaluation and care. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Depression and Anxiety in Persons with Von Willebrand Disease

Author

Roberts, Jonathan C., primary, Kulkarni, Roshni, additional, Kouides, Peter A., additional, Sidonio, Robert F., additional, Carpenter, Shannon L, additional, Konkle, Barbara A, additional, Wu, Joanne, additional, Ullman, Megan M., additional, Curtis, Randall, additional, Baker, Judith, additional, Crook, Nicole, additional, and Nichol, Michael B., additional

Published
2021
Full Text
View/download PDF

25. Evaluation for Bleeding Disorders in Suspected Child Abuse.

Author

Anderst, James, Carpenter, Shannon L., Abshire, Thomas C., and Killough, Emily

Subjects
*BLOOD coagulation tests, *CHILD abuse, *INTRACRANIAL hemorrhage, *VITAMIN deficiency, *PEDIATRICS, *BLOOD coagulation disorders, *WOUNDS & injuries, *BLOOD volume, *FAMILY history (Medicine), *VITAMIN K
Abstract

Bruising or bleeding in a child can raise the concern for child abuse. Assessing whether the findings are the result of trauma and/or whether the child has a bleeding disorder is critical. Many bleeding disorders are rare, and not every child with bruising/bleeding that may raise a concern for abuse requires an evaluation for bleeding disorders. However, in some instances, bleeding disorders can present in a manner similar to child abuse. Bleeding disorders cannot be ruled out solely on the basis of patient and family history, no matter how extensive. The history and clinical evaluation can be used to determine the necessity of an evaluation for a possible bleeding disorder, and prevalence and known clinical presentations of individual bleeding disorders can be used to guide the extent of laboratory testing. This clinical report provides guidance to pediatricians and other clinicians regarding the evaluation for bleeding disorders when child abuse is suspected. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Evaluating for Suspected Child Abuse: Conditions That Predispose to Bleeding.

Author

Carpenter, Shannon L., Abshire, Thomas C., Killough, Emily, and Anderst, James D.

Subjects
*PHYSICAL diagnosis, *CLINICAL pathology, *CHILD abuse, *PSYCHOLOGICAL vulnerability, *INTRACRANIAL hemorrhage, *BRUISES, *MEDICAL history taking, *DISEASE prevalence, *VICTIMS
Abstract

Child abuse might be suspected when children present with cutaneous bruising, intracranial hemorrhage, or other manifestations of bleeding. In these cases, it is necessary to consider medical conditions that predispose to easy bleeding or bruising.When evaluating for the possibility of bleeding disorders and other conditions that predispose to hemorrhage, it is important for pediatricians to consider the child's presenting history, medical history, and physical examination findings before initiating a laboratory investigation. Many medical conditions can predispose to easy bleeding. Before ordering laboratory tests for a disease, it is useful to understand the biochemical basis and clinical presentation of the disorder, condition prevalence, and test characteristics. This technical report reviews the major medical conditions that predispose to bruising or bleeding and should be considered when evaluating for abusive injury. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

27. A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE)

Author

Konkle,Barbara A, Quon,Doris V, Raffini,Leslie, Recht,Michael, Radulescu,Vlad C, Carpenter,Shannon L, Dunn,Amy L, Lu,Mei, Watt,Maureen, Konkle,Barbara A, Quon,Doris V, Raffini,Leslie, Recht,Michael, Radulescu,Vlad C, Carpenter,Shannon L, Dunn,Amy L, Lu,Mei, and Watt,Maureen

Abstract

Barbara A Konkle,1 Doris V Quon,2 Leslie Raffini,3 Michael Recht,4 Vlad C Radulescu,5 Shannon L Carpenter,6 Amy L Dunn,7 Mei Lu,8 Maureen Watt9 1Department of Medicine, The University of Washington and Bloodworks Northwest, Seattle, WA, USA; 2Orthopaedic Hemophilia Treatment Center, Orthopaedic Institute for Children, Los Angeles, CA, USA; 3Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 4The Hemophilia Center, Oregon Health & Science University, Portland, OR, USA; 5Department of Pediatric Hematology and Oncology, University of Kentucky Medical Center, Lexington, KY, USA; 6Department of Hematology/Oncology, Children’s Mercy Hospital, Kansas City, MO, USA; 7Hemophilia Treatment Center, Nationwide Children’s Hospital and The Ohio State University College of Medicine, Columbus, OH, USA; 8Takeda Development Center Americas, Inc, Lexington, MA, USA; 9Outcomes Research & Epidemiology, Takeda Pharmaceuticals International AG, Zurich, SwitzerlandCorrespondence: Maureen WattTakeda Pharmaceuticals International AG, Thurgauerstrasse 130, Glattpark-Opfikon, Zurich, 8152, SwitzerlandTel +41 44 555 10 00Fax +41 44 555 10 01Email maureen.watt@takeda.comIntroduction: High collision-risk physical activity can increase bleeding risk in people with hemophilia A, as can increasing the time between factor VIII (FVIII) administration and physical activity. FVIII prophylaxis may be tailored to planned activities to prevent activity-related bleeding.Aim: To explore the relationship between physical activity levels, FVIII infusion timing, and occurrence of bleeding in patients with severe/moderately severe hemophilia A without FVIII inhibitors receiving antihemophilic factor (recombinant) (rAHF; ADVATE®; Baxalta US Inc., a Takeda company, Lexington, MA, USA).Methods: SPACE was a 6-month, prospective, multicenter, observational outcomes study (NCT02190149). Enrolled patients received an eDiary application and a wearable activity tracker, whi

Published
2021

28. Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B

Author

Buckner, Tyler W., primary, Carpenter, Shannon L, additional, Croteau, Stacy E., additional, Cuker, Adam, additional, Daoud, Nabil, additional, Kempton, Christine L, additional, Malec, Lynn M, additional, McLean, Thomas W., additional, Raffini, Leslie J., additional, Staber, Janice M, additional, Wang, Michael, additional, Watson, Crystal, additional, Zia, Ayesha, additional, and Recht, Michael, additional

Published
2020
Full Text
View/download PDF

30. Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices

Author

Ragni, Margaret V., primary, Xavier, Frederico, additional, Seaman, Craig D., additional, Acharya, Suchitra, additional, McGuinn, Catherine E., additional, Werner, Eric J., additional, Lawrence, Courtney Elizabeth, additional, Wheeler, Allison P., additional, Reiss, Ulrike, additional, Ayala, Irmel, additional, Cockrell, Erin, additional, Tarango, Cristina, additional, Dunn, Amy, additional, Kulkarni, Roshni, additional, Ahuja, Sanjay P, additional, Chitlur, Meera B., additional, Pipe, Steven W., additional, Malec, Lynn M, additional, Rodriguez, Vilmarie, additional, Crary, Shelley, additional, Brown, Deborah, additional, Diaz, Rosa, additional, Velez, Maria, additional, Leissinger, Cindy A., additional, Carpenter, Shannon L, additional, Knoll, Christine M., additional, Wang, Michael, additional, Young, Guy, additional, Thornburg, Courtney D, additional, Lasky, Joseph L, additional, Lucas, Tiffany Lin, additional, Hwang, Nina, additional, Vehec, Deborah, additional, Ivanco, Dana, additional, Haller, Tamara L., additional, Bertolet, Marnie, additional, and Brooks, Maria M, additional

Published
2020
Full Text
View/download PDF

33. Healthcare Utilization and Health Related Quality of Life in Persons with Von Willebrand Disease

Author

Roberts, Jonathan C., primary, Kulkarni, Roshni, additional, Kouides, Peter A., additional, Sidonio, Robert F., additional, Carpenter, Shannon L, additional, Konkle, Barbara A., additional, Wu, Joanne, additional, Baker, Judith, additional, Ullman, Megan M., additional, Curtis, Randall, additional, Carrasco, Steven, additional, Tran, Duc Quang, additional, and Nichol, Michael B., additional

Published
2020
Full Text
View/download PDF

34. U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Association between Family History and Age of Diagnosis

Author

Thornburg, Courtney D, primary, Friedman, Kenneth D, additional, Guerrera, Michael F, additional, He, Chunla, additional, Malec, Lynn M, additional, Simpson, Mindy L, additional, Tarantino, Michael D, additional, Van Den Berg, H. Marijke, additional, Watson, Crystal, additional, and Carpenter, Shannon L, additional

Published
2020
Full Text
View/download PDF

36. Practical considerations and consensus opinion for children’s hospital–basedinpatient hemostasis and thrombosis (HAT) consultative services: Communication from the ISTH SSCSubcommittee on Pediatric/Neonatal Thrombosis and Hemostasis

Author

Woods, Gary M., Raffini, Leslie, Brandão, Leonardo R., Jaffray, Julie, Branchford, Brian R., Ng, Christopher J., Sartain, Sarah E., Pak, Jennifer, Male, Christoph, Zia, Ayesha, Rizzi, Mattia, Sirachainan, Nongnuch, Faustino, Edward Vincent S., Carpenter, Shannon L., and Goldenberg, Neil A.

Abstract

Caring for children and adolescents with disorders of hemostasis and thrombosis (HAT) has become more specialized and requires a unique skill set that many providers are not able to obtain in standard pediatric hematology/oncology/bone marrow transplant fellowship training programs. The influx of numerous therapeutic advances and increasing medical complexity has expanded the need for experienced HAT providers and subspecialty collaboration in the inpatient setting due to the nuances in the management of patients with HAT complications and concerns. While there are data highlighting the benefits of an inpatient hemostasis, thrombosis, and anticoagulation management service in adult hospitals, there are limited pediatric data supporting such programs. In this article, we summarize the current practices of various pediatric institutions in the inpatient management of HAT patients and provide a consensus opinion for the development of a pediatric inpatient HAT service at tertiary care referral centers.

Published
2022
Full Text
View/download PDF

44. Why plasma‐derived factor VIII?

Author

Aledort, Louis, primary, Carpenter, Shannon L., additional, Cuker, Adam, additional, Kulkarni, Roshni, additional, Recht, Michael, additional, Young, Guy, additional, and Leissinger, Cindy, additional

Published
2019
Full Text
View/download PDF

48. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome

Author

Carpenter, Shannon L., primary, Goldman, Jennifer, additional, Sherman, Ashley K., additional, Selewski, David T., additional, Kallash, Mahmoud, additional, Tran, Cheryl L., additional, Seamon, Meredith, additional, Katsoufis, Chryso, additional, Ashoor, Isa, additional, Hernandez, Joel, additional, Supe-Markovina, Katarina, additional, D’alessandri-Silva, Cynthia, additional, DeJesus-Gonzalez, Nilka, additional, Vasylyeva, Tetyana L., additional, Formeck, Cassandra, additional, Woll, Christopher, additional, Gbadegesin, Rasheed, additional, Geier, Pavel, additional, Devarajan, Prasad, additional, Smoyer, William E., additional, Kerlin, Bryce A., additional, and Rheault, Michelle N., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results